Pharmaceutical intermediates

Tofacitinib Citrate Intermediates

4 pharmaceutical intermediates for Tofacitinib Citrate. Indication: Ankylosing Spondylitis (AS); Juvenile Rheumatoid Arthritis; Ulcerative Colitis; Psoriatic Arthritis; Rheumatoid Arthritis (RA).

提交项目 All intermediates

About Tofacitinib Citrate

Originator: Pfizer Inc
Indication: Ankylosing Spondylitis (AS); Juvenile Rheumatoid Arthritis; Ulcerative Colitis; Psoriatic Arthritis; Rheumatoid Arthritis (RA)
Approved Date: 11/06/2012
DS/DP: 12/08/2025

Available intermediates

4 intermediates currently listed for Tofacitinib Citrate. Request specifications, documentation or a quotation for any item below.

Tofacitinib Citrate intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
（3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidinamine HCL	1062580-52-2	/	/
4-Chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine	479633-63-1	/	/
1-benzyl-4-methylpiperidin-3-one	32018-96-5	/	/
N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine	477600-74-1	/	/

Other programs under T

Tazemetostat Hydrobromide Tazobactam Sodium Tegoprazan Tenapanor Hydrochloride Teneligliptin Tetrabenazine Tezacaftor Tianeptine sodium salt

Building toward Tofacitinib Citrate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →